deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 6-arm NCT04575597

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.

Sponsor: Merck Sharp & Dohme LLC

Conditions Coronavirus Disease (COVID-19)
Interventions Molnupiravir Placebo
Updated 20 times since 2020 Last updated: Jun 5, 2023 Started: Oct 19, 2020 Primary completion: May 5, 2022 Completion: May 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Coronavirus Disease (COVID-19) and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 20 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

20 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

▶ Show 15 earlier versions

  1. Apr 2023 — Jul 2023 [monthly]

    Completed PHASE2_PHASE3

  2. Feb 2023 — Apr 2023 [monthly]

    Completed PHASE2_PHASE3

  3. Jun 2022 — Feb 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  4. Dec 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Nov 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2_PHASE3

  7. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2_PHASE3

  9. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2_PHASE3

  10. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2_PHASE3

  11. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2_PHASE3

  12. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2_PHASE3

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  14. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  15. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Alcorcón, Spain , Atlantis, United States , Barcelona, Spain , Barranquilla, Colombia , Bellaire, United States , Belo Horizonte, Brazil , Bento Gonçalves, Brazil , Berlin, Germany and 116 more locations